mood regulation: nootropics and compounds | sci-wiki

Amibegron

Amibegron approached depression and anxiety from a genuinely unusual angle, agonizing the atypical beta-3 adrenergic receptor rather than touching serotonin transporters or GABA-A directly, on preclinical evidence that beta-3 stimulation increased serotonin and tryptophan levels and blunted stress-induced behavioral changes in rodents. Sanofi-Aventis pushed it all the way to worldwide Phase III trials for both depression and generalized anxiety disorder, a serious late-stage bet on a first-in-class mechanism. The trials came back unconvincing on efficacy, and Sanofi discontinued the program in 2008, leaving beta-3 adrenergic agonism as one of the more interesting mechanistic roads not taken in modern psychopharmacology.

reference

Serotonergic

Elzasonan

Elzasonan was Pfizer's bet on serotonin autoreceptor blockade as an SSRI booster; rather than being a standalone antidepressant, it was designed as a 5-HT1B/1D receptor antagonist meant to be added on top of sertraline to accelerate or deepen the antidepressant response, the same augmentation logic that pindolol trials had explored years earlier. The combination program moved through clinical testing but was shelved in 2008 with no efficacy data ever published, a quiet ending typical of augmentation strategies that could not clear the bar. Its main legacy is as a pharmacological tool compound used to characterize 5-HT1B/1D receptor pharmacology in the lab, long after the clinical program folded.

reference

Serotonergic

Gepirone

Gepirone spent more than two decades in regulatory purgatory before it ever reached a pharmacy shelf, and its story is really about how brutal the FDA approval bar can be even for a drug that eventually worked. Fabre-Kramer Pharmaceuticals (with Organon as an early partner) submitted gepirone for depression in the late 1990s and got rejected in 1999, then again after resubmission in 2001, again in 2003 to 2004, and a fourth time in 2007, each rejection hinging on inconsistent trial results even as some studies showed real separation from placebo. The company kept the compound alive through a formal dispute appeal granted in 2016, and the FDA finally approved gepirone extended-release as Exxua for major depressive disorder in September 2023, an almost 25-year odyssey from first submission to market. It is less a lost drug than a drug that got found again, after nearly disappearing for good.

reference

Neuropeptide

Nelivaptan

Nelivaptan chased a genuinely novel idea in psychiatry, blocking the vasopressin V1b receptor instead of tuning serotonin or GABA, on the logic that vasopressin drives the body's stress and HPA-axis response and that dialing it down might relieve anxiety and depression without the sedation or dependence baggage of benzodiazepines. Sanofi-Aventis ran it through four large, well-controlled Phase II trials for major depressive disorder and generalized anxiety disorder between 2006 and 2008, comparing it against escitalopram and paroxetine. The results were unambiguous in the wrong direction; nelivaptan showed no meaningful benefit over placebo in GAD and only inconsistent signals in depression, closing the book on vasopressin antagonism as an anxiety treatment for over a decade.

reference

Nootropic

OPC-14523

Otsuka Pharmaceutical in Japan built OPC-14523 to hit two antidepressant-relevant targets in one molecule, sigma receptors and the 5-HT1A receptor, without directly blocking the serotonin transporter the way an SSRI does. In rodent screens it cut immobility in the forced swim test, increased dorsal raphe serotonergic neuron firing with repeated dosing, and reversed both scopolamine-induced and age-associated memory impairment, a combination antidepressant and pro-cognitive profile that made it a heavily cited pharmacology tool through the early 2000s. There is no public record of it reaching a pivotal human depression trial; Otsuka's psychiatric pipeline moved in other directions, and OPC-14523 stayed a preclinical proof-of-concept rather than becoming a marketed drug.

reference

Neurosteroid

Org 34517

Org 34517 targeted a different piece of the depression puzzle entirely, the glucocorticoid receptor, on the theory that chronically elevated cortisol signaling drives depressive symptoms, especially in psychotic and melancholic depression where HPA-axis dysregulation is most pronounced. Organon (later folded into Merck/Schering-Plough) took it into Phase III, and an early paroxetine-controlled trial in 142 patients showed comparable antidepressant effects with a notable edge in patients who ran hypercortisolaemic. Despite that promising signal, the program stalled inside the corporate mergers that consumed Organon in the late 2000s, and the compound resurfaced years later, rebranded as PT-150, in the hands of a small biotech pursuing it for entirely different indications. It is one of the clearer cases of a molecule losing momentum not to failed science, but to a failed company.

reference

Dopaminergic

Radafaxine

Radafaxine is the single-isomer version of a molecule most people have already taken without knowing it, the active (2S,3S)-hydroxybupropion metabolite that does a good chunk of the work in ordinary bupropion. GlaxoSmithKline isolated and purified this metabolite hoping a cleaner single-enantiomer dopamine reuptake inhibitor could outperform bupropion itself, and pushed it into trials across depression, bipolar disorder, obesity, fibromyalgia, and neuropathic pain. None of that data was ever published; GSK simply stopped the program, reportedly over underwhelming test results that could not justify differentiating it from a cheap generic parent drug. It stands as a reminder that isolating a drug's active metabolite does not automatically make a better medicine.

reference

Serotonergic

Robalzotan

Robalzotan was AstraZeneca's attempt to flip the SSRI script; instead of blocking reuptake, it selectively antagonized presynaptic 5-HT1A autoreceptors, a mechanism meant to speed up and amplify serotonin release compared to a standard SSRI. The theory was sound enough to carry it into a 385-patient, paroxetine-controlled Phase II depression trial, plus separate programs for irritable bowel syndrome and overactive bladder. None of it panned out; the depression trial showed no separation from placebo, and the GI and urology programs were quietly closed out by 2005. It is a clean case study in how a mechanistically elegant idea can still fail the only test that matters, a randomized trial.

reference

Sigma-1 Agonist

Siramesine

Siramesine came out of H. Lundbeck's sigma-receptor chemistry program in Denmark in the mid-1990s, and it is still one of the most selective sigma-2 ligands ever made, with subnanomolar affinity and roughly 140-fold preference for sigma-2 over sigma-1. It moved into human testing for anxiety and depression on the strength of strong anxiolytic- and antidepressant-like signals in rodent models. Lundbeck quietly shelved the psychiatric program in the mid-2000s without publishing a clear efficacy failure; the company's own statements pointed to commercial rather than safety reasons. The molecule did not disappear, though; oncology researchers picked it back up because at higher concentrations it destabilizes lysosomal membranes and kills tumor cells, giving siramesine a stranger second career than most abandoned psychiatric drugs get.

reference

Serotonergic

Tandospirone

Tandospirone is a case of a drug that succeeded, just never where most of the archive's audience would notice; the azapirone was approved and marketed in Japan in 1996 as Sediel for generalized anxiety disorder, and later in China in 2004, where it remains in clinical use today for anxiety and, off-label, mood and psychotic-adjunct indications. It never sought FDA approval and stayed almost entirely off the radar in the US and Europe, overshadowed first by benzodiazepines and later by SSRIs. Its main pharmacological claim to fame is being one of the most selective 5-HT1A partial agonists among the azapirones, with comparatively little dopamine D2 or off-target receptor activity compared to relatives like buspirone.

reference